Fezin-CI

Clinical Trials

Extensive clinical trials have established the efficacy and safety of citalopram for its approved indications. Ongoing post-marketing surveillance and studies continue to monitor its profile.

Lab Monitoring

• Electrolytes (especially sodium) if hyponatremia is suspected
• ECG monitoring in patients with cardiac risk factors or on higher doses

Doctor Notes

• Assess for suicidality, especially in young patients and at initiation/dose changes.
• Monitor for QT prolongation, especially in patients with pre-existing cardiac conditions or on concomitant QT-prolonging drugs.
• Gradual tapering is essential to avoid withdrawal symptoms.

Patient Guidelines

• Take as directed by your doctor.
• Do not stop taking abruptly, as withdrawal symptoms may occur. Gradually reduce dose under medical supervision.
• Be aware of increased suicidal thoughts, especially at the beginning of treatment or after dose changes.
• Avoid alcohol while taking this medicine.

Missed Dose Advice

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.

Driving Precautions

May cause dizziness or drowsiness. Avoid driving or operating heavy machinery until you know how this medicine affects you.

Lifestyle Advice

• Engage in regular physical activity.
• Maintain a balanced diet.
• Practice stress-reduction techniques like mindfulness or meditation.
• Ensure adequate sleep.